Substance + claimed effects

Ginger is the rhizome of Zingiber officinale, used as a culinary spice across most cuisines and as a concentrated extract in capsule, powder, and tea form. Its pharmacologically active fraction is the gingerols — chiefly 6-gingerol, the dominant pungent compound in fresh rhizome — and their dehydrated cousins, the shogaols (chiefly 6-shogaol), which form when ginger is dried or heated Mashhadi et al. 2013. This entry covers ginger as taken regularly by adults, whether in food or as a 0.5–2 g/day powdered extract, and the consequences with the strongest evidence base: anti-nausea action (pregnancy, chemotherapy, post-operative, motion), acceleration of gastric emptying and effect on functional dyspepsia, reduction of inflammatory markers and musculoskeletal/exercise-related pain, modest improvements in fasting glucose and HbA_1c in type-2 diabetes, and reduction of primary dysmenorrhoea pain. Out of scope: oncological chemopreventive claims (preclinical only) and cardiovascular hard endpoints (cohort data too thin).

Evidence by addressing question

mechanism

The anti-emetic effect runs through multiple receptors. 6-gingerol and 6-shogaol are 5-HT₃ receptor antagonists in the enteric nervous system — the same receptor class targeted by ondansetron — and also act at muscarinic M3 and substance-P/NK1 sites, blocking the afferent vagal traffic that triggers vomiting Marx et al. 2013, Mashhadi et al. 2013. Peripherally, ginger stimulates antral contractions and accelerates gastric emptying: in a crossover trial of 24 healthy volunteers, 1.2 g of ginger powder reduced gastric emptying half-time from 16.1 to 12.3 min and produced antral motor activity within ~30 min of ingestion Wu et al. 2008. This dual mechanism — central anti-emetic plus pro-kinetic — explains why ginger calms nausea without delaying gastric clearance the way some 5-HT₃ antagonists do.

The anti-inflammatory and analgesic effects derive from inhibition of arachidonic-acid metabolism. Gingerols and shogaols inhibit both COX-2 and 5-LOX, suppressing prostaglandin E₂ and leukotriene B₄, and downregulate NF-κB signalling, with downstream reductions in TNF-α, IL-1β, and IL-6 in vitro and in small human RCTs Mashhadi et al. 2013, Mozaffari-Khosravi et al. 2014. This is also the mechanistic basis for the dysmenorrhoea effect — menstrual pain is largely prostaglandin-mediated. 6-shogaol additionally activates TRPV1, producing the warmth and mild analgesia recognisable from a strong ginger tea.

Glucose effects are less mechanistically nailed down. Candidate pathways include inhibition of intestinal α-glucosidase and α-amylase (slowing carbohydrate absorption), AMPK activation in muscle and hepatocytes, and improved insulin sensitivity downstream of reduced low-grade inflammation Anh et al. 2020. Effect sizes are modest; the mechanism is multifactorial rather than dominant on any single pathway.

evidence

Across 109 RCTs reviewed in 2020, ginger has its strongest, most replicated evidence in nausea/vomiting and the most consistent biomarker movement in glycaemic and inflammatory endpoints; signals on other organ systems are weaker or preliminary Anh et al. 2020.

Nausea — pregnancy. The 2014 meta-analysis of 12 RCTs (n = 1278) found that 1.0–1.5 g/day ginger over 3–21 days significantly improved nausea symptoms versus placebo and was non-inferior to vitamin B₆; no increase in spontaneous abortion, stillbirth, or congenital anomaly was observed Viljoen et al. 2014. ACOG's practice bulletin lists ginger as a first-line non-pharmacological option for nausea and vomiting of pregnancy.

Nausea — chemotherapy. A URCC CCOP four-arm RCT of 576 patients receiving moderately or highly emetogenic chemotherapy added ginger 0.5 g, 1.0 g, or 1.5 g daily (starting 3 days before chemo) or placebo to a standard 5-HT₃ antagonist regimen. All three ginger doses significantly reduced acute (day-1) chemotherapy-induced nausea severity; the 0.5–1.0 g doses outperformed 1.5 g Ryan et al. 2012. The 2013 systematic review of seven RCTs concluded that ginger is a promising adjunctive antiemetic, with effect mostly on acute (not delayed) emesis and best results when started before chemotherapy Marx et al. 2013.

Nausea — post-operative. The 2006 meta-analysis pooled five RCTs (n = 363) and found that 1 g of ginger taken pre-operatively reduced 24 h post-operative nausea (RR 0.69, 95% CI 0.54–0.89) and vomiting (RR 0.61, 95% CI 0.45–0.84) versus placebo Chaiyakunapruk et al. 2006. Effect size comparable to a single 4 mg dose of ondansetron in those trials.

Nausea — motion sickness. In a circular-vection model of motion sickness (n = 13 healthy adults), 1 g of powdered ginger reduced both subjective nausea symptoms and the gastric tachyarrhythmias (3–9 cpm slow-wave dysrhythmias) that mark motion-sickness onset Lien et al. 2003. This is the smallest of the nausea trials and animal data is mixed, but the consistent finding across controlled provocations is real.

Gastric motility / functional dyspepsia. In addition to Wu et al. 2008's acceleration of gastric emptying in healthy volunteers, a crossover trial in functional-dyspepsia patients (n = 11) found that 1.2 g of ginger reduced gastric emptying half-time from 12.6 to 7.5 min, though this did not translate to symptom improvement over the short observation window Hu et al. 2011. The pro-kinetic effect is real and consistent; the symptom benefit in chronic functional dyspepsia is less established.

Inflammation + pain. The 2015 meta-analysis of five RCTs in knee osteoarthritis (n = 593) found that ginger 0.5–1 g/day for 3–12 weeks produced a statistically significant but modest reduction in pain (SMD −0.30, 95% CI −0.50 to −0.09) and disability (SMD −0.22) versus placebo, with mild GI side effects more common in the ginger arms (RR 2.33) Bartels et al. 2015. The authors classified evidence quality as "modest" — fewer than half of trials were low risk of bias. Black et al.'s 11-day eccentric-exercise RCT (n = 74) found that 2 g/day of raw or heated ginger reduced delayed-onset muscle soreness by ~25% at 24 h post-exercise Black et al. 2010. Inflammatory cytokines (TNF-α, IL-1β, hs-CRP) move modestly downward in small RCTs of older adults and patients with chronic disease Mozaffari-Khosravi et al. 2014.

Blood glucose. In a 12-week double-blind RCT (n = 70, type-2 diabetes), 2 g/day of ginger powder reduced fasting blood glucose by ~11%, HbA_1c by ~0.5 percentage points (from 8.2 to 7.7), and ApoB/ApoA-I ratio compared with placebo Khandouzi et al. 2015. Meta-analyses of ~8–10 trials in T2D consistently find fasting glucose reductions of 0.4–1.1 mmol/L and HbA_1c reductions of ~0.3–0.5 percentage points — clinically modest but real Anh et al. 2020. No meaningful effect demonstrated in non-diabetic populations.

Menstrual pain (dysmenorrhoea). The 2015 meta-analysis of six RCTs (n ≈ 500) found that 750 mg–2 g/day of ginger powder during the first 3–4 days of menses significantly reduced dysmenorrhoea pain versus placebo (effect size moderate-to-large; SMD ranging −1.3 to −0.8 across trials) Daily et al. 2015. Head-to-head trials show ginger 250 mg four times daily is non-inferior to mefenamic acid 250 mg and ibuprofen 400 mg for dysmenorrhoea pain relief Ozgoli et al. 2009. Evidence is among the strongest for any non-pharmacological dysmenorrhoea intervention.

protocol

Across the RCT literature, effective daily doses cluster at 0.5–2 g of powdered dried rhizome, equivalent to roughly 5–10 g of fresh root or ~4 cups of strong ginger tea (a thumb-sized piece of fresh ginger weighs ~10 g, of which ~5% is dry weight). For the highest-evidence indications: 1 g pre-operatively for PONV Chaiyakunapruk et al. 2006; 0.5–1 g/day starting 3 days before chemotherapy for CINV Ryan et al. 2012; 1–1.5 g/day in divided doses for pregnancy nausea Viljoen et al. 2014; 750 mg–2 g/day during the first 3–4 days of menstruation for dysmenorrhoea Daily et al. 2015; 2 g/day chronically for inflammatory and glycaemic effects Khandouzi et al. 2015. Onset for anti-emetic effect is ~30–60 min; plasma half-life of gingerols is ~2 h, so dividing into two or three doses extends coverage.

contraindications

Ginger has theoretical antiplatelet activity (inhibition of thromboxane synthesis), and a handful of case reports describe potentiation of warfarin's INR with high-dose ginger supplementation. RCTs at culinary and 2 g/day doses have not shown clinically significant effects on platelet aggregation, INR, or bleeding in healthy adults or in stable warfarin patients, but the safety signal is too small to confidently exclude an interaction at higher extract doses. Practical caution: anyone on warfarin, DOACs, or chronic aspirin should keep ginger to culinary amounts or coordinate higher doses with their prescriber Anh et al. 2020. High doses can cause heartburn or worsen reflux. Pregnancy data through 1.5 g/day is reassuring on miscarriage and congenital anomaly endpoints across 12 RCTs Viljoen et al. 2014; ACOG endorses use during pregnancy for nausea.

misconceptions

Three common misreads: (1) "Ginger settles the stomach by slowing things down" — the opposite, gastric emptying is accelerated, which is part of why it works for delayed-gastric-emptying nausea but can worsen reflux Wu et al. 2008. (2) "Anti-inflammatory like ibuprofen" — directionally yes (COX-2 inhibition), but effect size in OA is roughly a quarter to a third of NSAIDs; ginger is an adjunct, not a replacement, for inflammatory pain Bartels et al. 2015. (3) "Lowers blood sugar in everyone" — meaningful glucose effect is confined to type-2 diabetes and impaired fasting glucose; in healthy euglycaemic adults, ginger does not move fasting glucose or HbA_1c Anh et al. 2020.

alternatives

For pregnancy nausea: vitamin B₆ (pyridoxine) is comparable in evidence and routinely combined with doxylamine in the US/Canada (Diclegis/Diclectin); ginger and B₆ show similar effect sizes and are often tried sequentially. For CINV: 5-HT₃ antagonists (ondansetron) remain first-line and far more potent for highly emetogenic regimens; ginger is adjunctive. For PONV: ondansetron, dexamethasone, and acupressure at PC6 (P6/Neiguan) all have RCT evidence; ginger is one option among several with comparable effect sizes for moderate-emetic-risk surgery Chaiyakunapruk et al. 2006. For dysmenorrhoea: NSAIDs (ibuprofen, mefenamic acid, naproxen) are first-line; ginger is non-inferior in head-to-head trials but with slower onset and slightly weaker peak effect Ozgoli et al. 2009. For OA pain: exercise (the highest-evidence intervention by far), weight loss, topical NSAIDs, paracetamol, oral NSAIDs; ginger sits below all of these in effect size.

failure-modes

The two recurring reasons ginger underperforms in real life: dose is too low (a slice in stir-fry or one ginger tea bag delivers ~100–300 mg of dried-equivalent gingerols, well below the 1–2 g daily total used in trials) and form is wrong for the indication (raw juice or fresh root for chronic glucose/inflammation effects, where the trials almost all used standardized powdered extract; the gingerol-to-shogaol ratio differs and dosing is hard to estimate from food). For acute nausea, fresh or candied ginger works; for chronic indications, a measured supplement is more reliable.

practicalities

Fresh ginger root is sold per pound in essentially every grocery store globally and is among the cheapest spice-shelf interventions in the catalogue; a year of culinary use is typically under $30. Powdered standardized extract (4–5% gingerols) is widely available, ~$15–25/month for 1–2 g/day. No prescription, no clinician visit, no monitoring. Storage: fresh root keeps ~3 weeks in the fridge or ~6 months frozen.

The credibility range

Optimist case

Ginger is the rare botanical with both a coherent multi-receptor mechanism (5-HT₃, COX-2, NF-κB, TRPV1) and a deep RCT base — 109 trials reviewed in 2020 Anh et al. 2020. It is non-inferior to ondansetron 4 mg for PONV at a single 1 g dose Chaiyakunapruk et al. 2006; non-inferior to ibuprofen 400 mg for primary dysmenorrhoea Ozgoli et al. 2009; the only oral antiemetic with safety data in pregnancy supporting routine use Viljoen et al. 2014; and reduces HbA_1c by ~0.5 percentage points in T2D, on par with some pharmaceutical add-ons Khandouzi et al. 2015. Cost, side-effect profile, and accessibility are unmatched. The case for keeping it in the house is overwhelming.

Skeptic case

Most ginger trials are small (n < 100), short (4–12 weeks), and conducted in single centres in Iran, Thailand, and Australia rather than as large multi-centre Western trials; publication bias is plausible and the OA meta-analysis explicitly flagged it Bartels et al. 2015. Effect sizes outside nausea are modest: SMD −0.30 in OA pain (clinical-significance threshold is typically −0.4 to −0.5); fasting glucose drops of ~10% in T2D are real but unlikely to change clinical decisions; the inflammation-marker movements are downstream surrogates, not hard endpoints. Standardization across products is poor — gingerol content varies 3-fold between commercial powders. And the central-pharmacology cleanness is overstated: ginger does not match ondansetron for highly emetogenic chemo. Skeptic call: useful for self-limited nausea and as a low-cost adjunct, oversold for chronic disease.

Author's call

Lean optimist on the nausea cluster (pregnancy, CINV adjunctive, PONV, motion) and on dysmenorrhoea — the evidence is mature, multi-trial, and consistent. Lean cautious on chronic indications (OA, T2D, inflammation): effects are real but modest, and the smart positioning is "low-cost adjunct on top of first-line treatment", not "alternative to the first-line treatment". Evidence overall is a 3 — strong on one cluster, modest-and-mixed on another, with mechanism credible across both. Controversy is low (1) — the field broadly agrees on what ginger does and where the evidence ends.

Stakeholder + incentive map

• Supplement industry markets standardized ginger extract for nausea, OA, glucose, and "general inflammation" — financial incentive to oversell chronic-disease claims where the data is weakest.
• Obstetrics (ACOG, RCOG) endorses ginger as first-line non-pharmacological for nausea and vomiting of pregnancy — guidelines aligned with the evidence.
• Oncology supportive care (NCCN, MASCC) lists ginger as an option for CINV but not a primary recommendation — appropriate hedging given adjunctive nature.
• Traditional medicine systems (Ayurveda, TCM) have used ginger for ~2000 years for nausea, digestion, and "cold" conditions — historical practice that anticipated the modern mechanism.
• Pharma has limited incentive to study a cheap unpatentable rhizome; this is part of why high-quality multi-centre trials are scarce.

Population variability

• Pregnant women — best-evidenced population for the anti-nausea effect; safety profile robust through 1.5 g/day Viljoen et al. 2014.
• Chemotherapy patients — effect demonstrated in mixed-cancer cohorts on moderate-to-high emetogenic regimens, started before chemo; less helpful if started after symptoms begin Ryan et al. 2012.
• Women with primary dysmenorrhoea — robust effect; secondary dysmenorrhoea (endometriosis, fibroids) is less studied and likely needs different treatment.
• Type-2 diabetics — glycaemic effects clearest here; not seen in healthy controls Anh et al. 2020.
• Adults on warfarin/DOACs/aspirin — theoretical interaction; culinary doses safe, supplemental doses warrant clinician coordination.
• Reflux/GERD sufferers — the pro-kinetic effect can be either helpful (gastroparetic phenotype) or worsen symptoms (reflux phenotype); individual response varies.
• Children — most trials in adults; ginger is used in paediatric anti-emetic protocols anecdotally but evidence is thin.

Knowledge gaps

Open questions: (1) cardiovascular hard endpoints — does the modest reduction in lipids, glucose, and inflammatory markers translate to MACE reduction? No long-term outcomes trial exists. (2) Optimal form and standardization — fresh vs powder vs standardized extract, gingerol-to-shogaol ratio, with-food vs fasted. (3) Comparative effectiveness against 5-HT₃ antagonists for highly emetogenic chemotherapy at higher ginger doses (3+ g) has not been tested. (4) Bleeding/anticoagulant interaction at supplemental doses — current safety signal rests on small trials and case reports, not on adequately powered pharmacokinetic studies. (5) Whether the gastric pro-kinetic effect translates to chronic functional-dyspepsia symptom relief over months has not been studied with the right trial design. Evidence that would change the author's call: a large multi-centre trial showing meaningful glycaemic effect in pre-diabetic adults (would raise the longevity score), or a pharmacokinetic interaction study confirming clinically significant anticoagulant potentiation at 2 g/day (would raise controversy and tighten contraindications).

Scope vs. brief. The brief named nausea, postprandial gastric motility, inflammatory and pain markers, blood glucose, and menstrual pain. The article covers all five end-to-end. The gastric-motility material is folded into the mechanism + misconceptions sections rather than getting its own addressing section because the felt-experience hook for the average reader is nausea relief, not motility per se; the motility data is the why, not the standalone what. Editor reviewing should check this call.

What was deliberately excluded.

• Preclinical chemopreventive claims (anti-cancer activity in cell lines and rodents) — meaningful preclinical signal but no human outcomes trials; including would have inflated the longevity score on the strength of bench data, which the catalogue's evidence bar doesn't allow.
• Cardiovascular hard endpoints. Biomarker movements (lipids, glucose, CRP) are real; no long-term MACE or mortality trial exists. Reflected by capping longevity at 1.
• Cognitive / Alzheimer's claims. Animal-model anti-neuroinflammatory data only; no human trials worth citing. Excluded entirely rather than wedged into focus or mood.
• Ginger's role in TCM and Ayurveda — touched briefly in the stakeholder map of the research dossier but kept out of the article because the entry is reader-action focused, not historical.

Hard scoring calls.

• health_short_term: 3 — could plausibly be a 4 for the people in the specific use-cases (pregnancy, chemo, dysmenorrhoea), where the felt-experience effect is substantial. Landed at 3 because the holistic score has to average across all readers and most won't be in those use-cases on any given day. The pitch leads with the strongest use-cases to do that work instead.
• evidence: 3 rather than 4 — anchored to the chronic-disease cluster, where trials are small and single-centre. The nausea + dysmenorrhoea cluster alone would justify a 4; averaged across the whole substance, 3 is the honest call.
• controversy: 1 rather than 0 — minor pushback exists on whether the OA pain effect crosses the clinical-significance threshold (SMD -0.30 sits below the usual -0.40 to -0.50 line), and on the warfarin interaction signal. Not enough to warrant 2.
• cadence: as-needed rather than daily — the highest-leverage uses are episodic (surgery, chemo, period, motion). Daily ginger is fine but mostly low-impact for healthy adults. "As-needed" matches the action the reader is most likely to take after reading.

Contraindication call. Listed blood-thinners. Did not list pregnancy because the dossier's safety signal through 1.5 g/day is reassuring and ACOG endorses it; flagging pregnancy as a contraindication would block the most-evidenced use.

Dream-narrative call. Overall score ~23, below the 40 obligatory line. Wrote a brief relief-lever narrative anyway because the honest hook ("the antiemetic was in the kitchen the whole time") supports it; the dek and tagline both crank from it.

Future links to wire when they exist.

• vitamin-b6 (alternative pregnancy antiemetic)
• pc6-acupressure (alternative motion + post-op antiemetic)
• peppermint-oil (IBS / cramping adjacent)
• ibuprofen or a broader NSAIDs entry (dysmenorrhoea + OA alternative)
• knee-osteoarthritis-exercise (the dominant lever ginger sits underneath)

Separate-entry candidates surfaced during the write. None worth flagging; the substance is unified enough that one entry covers it cleanly.